Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Liabilities: 2016-2024

Historic Total Liabilities for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $294.5 million.

  • UroGen Pharma's Total Liabilities rose 8.69% to $300.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $300.5 million, marking a year-over-year increase of 8.69%. This contributed to the annual value of $294.5 million for FY2024, which is 20.94% up from last year.
  • UroGen Pharma's Total Liabilities amounted to $294.5 million in FY2024, which was up 20.94% from $243.5 million recorded in FY2023.
  • Over the past 5 years, UroGen Pharma's Total Liabilities peaked at $294.5 million during FY2024, and registered a low of $25.6 million during FY2020.
  • In the last 3 years, UroGen Pharma's Total Liabilities had a median value of $243.5 million in 2023 and averaged $254.3 million.
  • Data for UroGen Pharma's Total Liabilities shows a peak YoY soared of 334.05% (in 2021) over the last 5 years.
  • UroGen Pharma's Total Liabilities (Yearly) stood at $25.6 million in 2020, then soared by 334.05% to $111.3 million in 2021, then soared by 102.08% to $225.0 million in 2022, then climbed by 8.24% to $243.5 million in 2023, then grew by 20.94% to $294.5 million in 2024.